Beijing, March 13, 2024 - National Health Commission of the People’s Republic of China issued an announcement approving several food additives. Among them, Abiochem's independently developed Enzymatically Produced Steviol Glycosides has successfully passed the approval process.

Shanghai, November 16th, 2022 – Recently, Abiochem announced its nomination as one of the forth batch national-level “little giant” enterprises, published by the Ministry of Industry and Information Technology (MIIT).

SHANGHAI, September 26, 2021 - Abiochem has cooperated with a leading diabetes company，Tonghua Dongbao Pharmaceutical Co., Ltd. （600867.SH) to produce a generic version of Sitagliptin, and gets approved by CDC (Chinese Center for Disease Control and Prevention) recently. This drug is the first domestic generic drug manufactured based on "non-hydrolase" biosynthetic methods, opening up a new chapter in biosynthetic pharmaceuticals.

Chongqing, July 21, 2022 – Abiochem today announced the opening of a new production base in Changshou District, Chongqing Province.

SHANGHAI, July 29, 2022 – Abiochem announced its selection as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2021. Abiochem was chosen for its innovative R&D ability and industrialization progress in synthetic biology.

GUANGDONG, April 19, 2021 – Abiochem has been invited to attend the 30th meeting of the third deputy council held by the Chinese Chemical Society at Zhuhai International Convention & Exhibition Center, Guangdong, on April, 19th, 2021.

CHONGQING, June 18, 2021 - Abiochem today announced that it has signed an investment agreement with the government of Chongqing Changshou District to build a new manufacturing site.

SHANGHAI, January 24, 2022 – Abiochem today announced a strategic cooperation with Anhui Jinhe Industrial Co., Ltd. (002597.SZ), a major sweeteners manufacturer in China, and jointly promote cooperation on sugar substitute and non-nutritive sweeteners with the help of synthetic biotechnology.